TREATMENT WITH MDL 72527 AMELIORATED CLINICAL SYMPTOMS, RETINAL GANGLION CELL LOSS, OPTIC NERVE INFLAMMATION, AND IMPROVED VISUAL ACUITY IN AN EXPERIMENTAL MODEL OF MULTIPLE SCLEROSIS

Treatment with MDL 72527 Ameliorated Clinical Symptoms, Retinal Ganglion Cell Loss, Optic Nerve Inflammation, and Improved Visual Acuity in an Experimental Model of Multiple Sclerosis

Multiple Bicycle Trainers Sclerosis (MS) is a highly disabling neurological disease characterized by inflammation, neuronal damage, and demyelination.Vision impairment is one of the major clinical features of MS.Previous studies from our lab have shown that MDL 72527, a pharmacological inhibitor of spermine oxidase (SMOX), is protective against neu

read more




Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature

Background: Retesting for Human epidermal growth factor receptor-2 (HER2) in post-neoadjuvant therapy resection is variable, and data is conflicting regarding the prognostic significance of changes in HER2 expression pre and post therapy.Methods: We identified 104 patients with localized HER2 IHC 3+ breast cancer who received neoadjuvant trastuzuma

read more